SG11201911597YA - B4galt1 variants and uses thereof - Google Patents

B4galt1 variants and uses thereof

Info

Publication number
SG11201911597YA
SG11201911597YA SG11201911597YA SG11201911597YA SG11201911597YA SG 11201911597Y A SG11201911597Y A SG 11201911597YA SG 11201911597Y A SG11201911597Y A SG 11201911597YA SG 11201911597Y A SG11201911597Y A SG 11201911597YA SG 11201911597Y A SG11201911597Y A SG 11201911597YA
Authority
SG
Singapore
Prior art keywords
b4galt1
variants
b4galt1 variants
Prior art date
Application number
SG11201911597YA
Other languages
English (en)
Inventor
May Montasser
Hout Cristopher Van
Alan Shuldiner
Giusy Gatta
Matthew Healy
Marja Puurunen
Original Assignee
Regeneron Pharma
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Univ Maryland filed Critical Regeneron Pharma
Publication of SG11201911597YA publication Critical patent/SG11201911597YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01133—Xylosylprotein 4-beta-galactosyltransferase (2.4.1.133)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG11201911597YA 2017-06-05 2018-06-04 B4galt1 variants and uses thereof SG11201911597YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762515140P 2017-06-05 2017-06-05
US201762550161P 2017-08-25 2017-08-25
US201862659344P 2018-04-18 2018-04-18
PCT/US2018/035806 WO2018226560A1 (en) 2017-06-05 2018-06-04 B4galt1 variants and uses thereof

Publications (1)

Publication Number Publication Date
SG11201911597YA true SG11201911597YA (en) 2020-01-30

Family

ID=62705750

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911597YA SG11201911597YA (en) 2017-06-05 2018-06-04 B4galt1 variants and uses thereof

Country Status (14)

Country Link
US (2) US10738284B2 (https=)
EP (1) EP3635102B1 (https=)
JP (2) JP7661009B2 (https=)
KR (1) KR102624979B1 (https=)
CN (1) CN110997906B (https=)
AU (1) AU2018282072B2 (https=)
CA (1) CA3065938A1 (https=)
DK (1) DK3635102T3 (https=)
ES (1) ES3049196T3 (https=)
FI (1) FI3635102T3 (https=)
IL (1) IL271073B2 (https=)
MX (1) MX2019014661A (https=)
SG (1) SG11201911597YA (https=)
WO (1) WO2018226560A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014661A (es) 2017-06-05 2020-07-29 Regeneron Pharma Variantes de b4galt1 y usos de estas.
TW202145884A (zh) * 2020-03-04 2021-12-16 美商再生元醫藥公司 Ｂ４ｇａｌｔ１介導功能之囓齒動物模型
JP2025519286A (ja) 2022-06-01 2025-06-25 イー－セラピューティクス・ピーエルシー 発現および／または機能の阻害剤
CA3276262A1 (en) * 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
CN115960926A (zh) * 2022-12-30 2023-04-14 南方科技大学 一种mRNA及含有mRNA的药物
EP4562159A1 (en) * 2023-07-27 2025-06-04 e-therapeutics PLC Inhibitors of expression and/or function

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
JPH10510700A (ja) 1993-06-04 1998-10-20 アメリカ合衆国 アンチセンスオリゴヌクレオチドを用いてカポジ肉腫を治療する方法
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
AU7286696A (en) 1995-10-13 1997-05-07 F. Hoffmann-La Roche Ag Antisense oligomers
CA2236825A1 (en) 1995-11-21 1997-05-29 Icn Pharmaceuticals, Inc. Inhibition of tumor growth by antisense oligonucleotides for il-8 and il-8 receptor
WO1997029757A1 (en) 1996-02-15 1997-08-21 National Institutes Of Health Rnase l activators and antisense oligonucleotides effective to treat rsv infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
EP1476547B1 (en) 2002-01-23 2006-12-06 The University of Utah Research Foundation Targeted chromosomal mutagenesis using zinc finger nucleases
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP2806025B1 (en) 2002-09-05 2019-04-03 California Institute of Technology Use of zinc finger nucleases to stimulate gene targeting
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2005108415A2 (en) 2004-04-30 2005-11-17 Biogen Idec Ma Inc. Membrane associated molecules
US7374927B2 (en) 2004-05-03 2008-05-20 Affymetrix, Inc. Methods of analysis of degraded nucleic acid samples
KR20070060115A (ko) 2004-09-16 2007-06-12 상가모 바이오사이언스 인코포레이티드 단백질 생산을 위한 조성물 및 방법
WO2009025645A1 (en) 2007-08-22 2009-02-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Beta 1,4-galactosyltransferases with altered donor and acceptor specificities, compositions and methods of use
WO2009102820A2 (en) * 2008-02-11 2009-08-20 Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services Modified sugar substrates and methods of use
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
GB201000688D0 (en) * 2010-01-15 2010-03-03 Diagenic Asa Product and method
WO2011145121A1 (en) 2010-05-18 2011-11-24 Scatolificio Mogliani S.N.C. Di Mogliani Mauro E Andrea Cardboard box for stable stacking with other identical specimens
RU2444378C1 (ru) 2010-09-06 2012-03-10 Олег Германович Макеев Способ лечения коронарной недостаточности при моделируемой ишемии миокарда
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
EP4357457B1 (en) 2012-10-23 2024-10-16 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
WO2014093718A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
WO2014131833A1 (en) 2013-02-27 2014-09-04 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Gene editing in the oocyte by cas9 nucleases
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
MX2019014661A (es) 2017-06-05 2020-07-29 Regeneron Pharma Variantes de b4galt1 y usos de estas.

Also Published As

Publication number Publication date
AU2018282072B2 (en) 2024-06-27
JP2023113657A (ja) 2023-08-16
JP7661009B2 (ja) 2025-04-14
IL271073A (en) 2020-01-30
KR20200024772A (ko) 2020-03-09
DK3635102T3 (da) 2025-10-27
CN110997906B (zh) 2024-05-07
US10738284B2 (en) 2020-08-11
JP2020527329A (ja) 2020-09-10
CA3065938A1 (en) 2018-12-13
FI3635102T3 (fi) 2025-10-28
EP3635102A1 (en) 2020-04-15
US20180346888A1 (en) 2018-12-06
US12480103B2 (en) 2025-11-25
IL271073B2 (en) 2025-10-01
MX2019014661A (es) 2020-07-29
AU2018282072A1 (en) 2020-01-16
IL271073B1 (en) 2025-06-01
RU2019144018A3 (https=) 2022-03-04
CN110997906A (zh) 2020-04-10
ES3049196T3 (en) 2025-12-15
WO2018226560A1 (en) 2018-12-13
EP3635102B1 (en) 2025-08-13
KR102624979B1 (ko) 2024-01-16
US20200399617A1 (en) 2020-12-24
RU2019144018A (ru) 2021-07-09

Similar Documents

Publication Publication Date Title
IL267925B (en) hsd17b13 variants and their uses
IL274217A (en) Adenovirus and its uses
IL274219A (en) Adenovirus and its uses
IL287825A (en) Structures of sirp-alpha variant and their uses
IL254977B (en) Biological conjugates and their uses
IL264813B (en) 2-oxo-imidazopyridines and their use
PL3152226T3 (pl) Modyfikowane cyklopentapeptydy i ich zastosowania
SG11201911597YA (en) B4galt1 variants and uses thereof
IL274220A (en) Adenovirus and its uses
ZA201801052B (en) Combinations and uses thereof
EP3464572C0 (en) VARIANTS OF ACETYLSEROTONIN-O-METHYLTRANSFERASE AND USES THEREOF
IL265531A (en) N 3 -cyclically substituted thienouraciles and use thereof
IL269836B (en) Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use
IL264473A (en) GPR156 variants and their uses
ZA201805977B (en) Mycobacteriophages capable of delivering auto-luminescent elements and uses thereof
IL254241A0 (en) Etv2 and its uses
IL263682A (en) Antibiotic variants and their uses
IL273671A (en) Cornoline variants and their use
IL275211A (en) Fast and flexible segment chains - division
IL269843B (en) Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use
GB201707279D0 (en) Multiearphones and polyearphones
PH32017001093S1 (en) Ballpen and cap
GB2545167B (en) Cloches and use thereof
GB201719565D0 (en) Biomarker and uses thereof
GB201620551D0 (en) Enzymes and uses thereof